Vidyya Medical News Service
*
Volume 7 Issue 2 Published - 14:00 UTC 08:00 EST 2-Jan-2005 Next Update - 14:00 UTC 08:00 EST 3-Jan-2005
little clear gif used for spacer
.
*

Lilly issues response to British Medical Journal
In response to the British Medical Journal article dated 1 January 2005, entitled "FDA to review missing drug company documents," Eli Lilly and Company has issued a statement.  more

*
Health effects of tsunamis
Natural disasters do not necessarily cause an increase in infectious disease outbreaks. However, contaminated water and food supplies as well as the lack of shelter and medical care may have a secondary effect of worsening illnesses that already exist in the affected region.  more

*
Update #4: South and Southeast Asia earthquake and tsunamis
The death toll has risen to more than 125,000. Death rates will rise due to communicable diseases unless humanitarian assistance is provided promptly and is well coordinated.  more

 


*
What we learn about smallpox from movies - Fact or fiction
Over the years, the writers of fictional film and television programs and movies have chosen disease outbreaks as the central theme of their storylines. The screening of F/X network's movie Smallpox and the May 2002 ER finale are examples of this type of outbreak story, specific to smallpox. Telling this type of story in film or on television creates challenges for the writers and for audiences. Because of the immediacy of the film medium, scientific and medical facts have to be dramatized, leaving the audience with some very real misconceptions and questions about how smallpox spreads and the nature of this health threat.  more

*
FDA approves Pfizer's Lyrica(TM) for the treatment of the two most common forms of neuropathic (nerve) pain
Pfizer Inc has received approval from the U.S. Food and Drug Administration (FDA) to market Lyrica(TM) (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.  more

*
FDA approves Ventavis(TM) for the treatment of pulmonary arterial hypertension (PAH)
CoTherix, Inc. announced that following priority review, the U.S. Food and Drug Administration (FDA) has approved Ventavis(TM) (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms. PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is currently marketed by Schering AG in several European countries and Australia, and now will be made available in the U.S. through CoTherix. more

*
Prescribing and product information: Ventavis (iloprost)
Ventavis is a nebuliser solution. This clear, colourless solution is changed into an aerosol mist by a special machine called a nebuliser. Breathing in the mist carries Ventavis to the lungs, where it can work most effectively in the artery between heart and lungs. Get the full prescribing and product information in today's issue of Vidyya. more

 
little clear gif used for a space